CM
RPTX

Crestline Management’s Repare Therapeutics RPTX Stock Holding History

Crestline Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25,101
Closed -$779K – 180
2020
Q2 		$779K Buy
+25,101
New +$806K 0.14% 69

Other funds holding RPTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Crestline Management's RPTX Position: Q3 2020 in Review

Crestline Management sold out of Repare Therapeutics (RPTX) in Q3 2020, closing a stake of 25,101 shares — an estimated $779K sold.

Crestline Management first reported a position in RPTX in Q2 2020 and held it in 1 quarter. The position peaked at $779K in Q2 2020. 39 funds tracked by Wall St. Rank hold RPTX as of Q3 2020.

  • Crestline Management reported no remaining Repare Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Crestline Management sold 25,101 Repare Therapeutics shares in Q3 2020, an estimated $779K.
  • Crestline Management first reported a position in Repare Therapeutics in Q2 2020 and held it in 1 quarter.
  • Crestline Management's Repare Therapeutics position peaked at $779K in Q2 2020.
  • 39 funds tracked by Wall St. Rank held Repare Therapeutics as of Q3 2020.

Based on Crestline Management's 13F filing for Q3 2020, filed 13 Nov 2020.